GSEP
MYGN icon

Golden State Equity Partners’s Myriad Genetics MYGN Stock Holding History

Golden State Equity Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-100
Closed -$450 – 1216
2026
Q1 		$450 Buy
+100
New +$521 ﹤0.01% 1898

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Golden State Equity Partners's MYGN Position: Q2 2026 in Review

Golden State Equity Partners sold out of Myriad Genetics (MYGN) in Q2 2026, closing a stake of 100 shares — an estimated $450 sold.

Golden State Equity Partners first reported a position in MYGN in Q1 2026 and held it in 1 quarter. The position peaked at $450 in Q1 2026. 197 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

  • Golden State Equity Partners reported no remaining Myriad Genetics position as of Q2 2026 after selling out during the quarter.
  • Golden State Equity Partners sold 100 Myriad Genetics shares in Q2 2026, an estimated $450.
  • Golden State Equity Partners first reported a position in Myriad Genetics in Q1 2026 and held it in 1 quarter.
  • Golden State Equity Partners's Myriad Genetics position peaked at $450 in Q1 2026.
  • 197 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Golden State Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.